🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🚨 #TCT2024 White Sneaker Day is tomorrow! 🏃‍♂️✨ Rally your colleagues, lace up your white sneakers, & snap the ultimate group selfie! 📸👟 Tag your photos with #TCTWhiteSneakerDay! 👉 ow.ly/hWuO50TT143 David J. Cohen, MD, MSc Juan F. Granada Dr Roxana Mehran Sahil A. Parikh, MD Tricia Rawh

Presented at #TCT2024 | Novel #ELEGANCE Patient Preference Information (PPI) will help clinicians understand the experience of diverse patients & deliver more patient-centric, precision care by race, ethnicity & sex. #EvidenceBasedMedicine #healthequity #clinicaltrialdiversity

Headed to #TheVEINS24 and #VIVA24? Don't miss these Boston Scientific events! 🗓️ The VEINS Meeting The VIVA Foundation Jeff Mirviss

ROADSTER 3 30-day outcomes are in: TCAR delivers the lowest stroke rates in the first-ever independently adjudicated study for standard surgical risk patients. Learn More about the ROADSTER 3 Clinical Data: silkroadmed.com/healthcare-pro… Learn More about TCAR: silkroadmed.com/healthcare-pro…

🗓️Join us next week to discuss The "Usual" Intermediate-High Risk PE Case…And "What Else” - The Usual: Standard PE case - What Else: Case with PFO present - What Else: Case with very short duration, low dose lytic protocol Register Today: qrco.de/ViEWebinar

We’re excited to add TCAR technology to Boston Scientific’s portfolio. CAD is a rapidly growing therapy area affecting nearly half a million new patients annually in the US. As one company, we’re excited to bring this therapy to more patients. *Available only in US currently

Continue following Silk Road Medical’s journey, now as a part of #BostonScientific, by following Jeff Mirviss and Cat Jennings. #ForwardTogether #ENROUTE

Big news! Upon close and regulatory approval, we look forward to providing physicians and their patients access to this emerging, high-growth therapy for treatment of complex cardiovascular diseases.

Presented at #LINC2025 | TRUE-PTX data show that #PAD treatment with #paclitaxel #drugeluting devices may reduce the risk of amputation and readmission vs. treatment with non-drug devices. #TRUEPTX #EvidenceBasedMedicine

New data from a large, real-world study support the use of drug-eluting devices to reduce amputations, readmissions, and healthcare costs in the treatment of #PAD, Marianne Brodmann informed attendees at #LINC2025 vascularnews.com/drug-eluting-t…

Presented at #LINC2025 | Ranger ISR analysis from the #ELEGANCERegistry showed high 84.2% K-M rate of freedom from CD-TLR rate at 12m across this diverse and complex 150-patient population, which included nearly 50% females and over 30% under-represented minorities. #RangerISR

Exciting news! Boston Scientific has officially closed the acquisition of @BoltIVL. We look forward to enhancing our PI portfolio and providing physicians and their patients with this advanced, innovative therapy for complex vascular diseases. #BoltIVL #ATK #BTK

Join us for an enlightening discussion as thought leaders spanning diverse medical specialties share the latest clinical data & their perspectives on the future of #PE. PERT Consortium Keith Sterling Daniella KadianDodov Peter Monteleone, MD, FACC, FSCAI #MedEd Register now: bit.ly/42Uy0o7

Excited to share that our dedicated investigators, The PERT Consortium® & Universitätsmedizin Mainz, have enrolled the 500th patient in #HIPEITHO! HI-PEITHO is the seminal global prospective multicenter RCT with primary endpoints that will be meaningful to all who manage patients with #PE

🗓️ Join us at #NCVH2025 for a live case featuring an expert operator and panel who will discuss the application of #Ranger200cm to treat complex lesions and evidence-based decision making with #drugeluting therapies. #DCB #DrugCoatedBalloon #PAD

Introducing #ENROUTE: The first and only transcarotid artery revascularization (#TCAR) system that reverses blood flow during stenting to protect the brain. See why physicians are making the switch: bit.ly/44616RY #OnePowerfulSwitch *Available in US only

FDA-approved. Clinically proven. Minimally invasive. #RangerDCB brings next-gen performance to #PAD procedures. Explore the new 200cm monorail platform: bit.ly/46vrMxa #DCB

Big News! The 544th—and final—patient has been enrolled in #HIPEITHO, a landmark RCT comparing EKOS + anticoagulation vs. anticoagulation alone in intermediate-high risk #PE. Thank you to our investigators, The PERT Consortium® & Universitätsmedizin Mainz. Learn more: bit.ly/44VQapx